Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

Core Insights - Regeneron Pharmaceuticals has announced positive results from Phase 3 trials of its investigational allergen-blocking antibodies for treating moderate-to-severe cat and birch allergies, showing significant reduction in allergy symptoms compared to placebo [1][2][4][12] Cat Allergy Program - The cat allergy program involved two monoclonal antibodies, REGN1908 and REGN1909, targeting FelD1, the dominant cat allergen, which affects over 20 million patients in the U.S. [3][4] - In the Phase 3 trial, participants receiving the antibody combination showed a 52% reduction in ocular itch, 39% in conjunctival redness, and 44% in skin prick reactivity, all with high statistical significance [4][12] - The treatment was well-tolerated, with no serious adverse events reported, and further Phase 3 development is planned for the first half of 2026 [4][12] Birch Allergy Program - The birch allergy program utilized REGN5713 and REGN5715 monoclonal antibodies targeting BetV1, affecting over 10 million people in the U.S. [5][6] - In the Phase 3 trial, participants receiving the BetV1-blocking antibodies experienced a 51% reduction in ocular itch, 46% in conjunctival redness, and 44% in skin prick reactivity, all statistically significant [12] - Similar to the cat allergy trials, the birch allergy treatment was well-tolerated, with no serious adverse events, and additional Phase 3 development is expected to begin by the end of the year [12] Broader Allergy Pipeline - Regeneron is also conducting a proof-of-concept trial for severe food allergies, which involves a novel approach of ablating IgE-producing cells followed by treatment with Dupixent [7] - Initial results from the food allergy trial have been encouraging, with completion of enrollment expected by the end of the year [7] Technology and Innovation - Regeneron's VelocImmune technology, which produces fully human antibodies, has been instrumental in developing these investigational treatments [9][10] - The company has a strong track record of translating scientific discoveries into approved therapies, with a focus on serious diseases [10][11]